Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

SABS SAB Biotherapeutics Inc

2,5499

-0,1201 (-4,50%)

Zuletzt aktualisiert: 21:01:12

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

SAB Biotherapeutics (NASDAQ:SABS)
Historical Stock Chart
Von Aug 2024 bis Sep 2024

Click Here for more SAB Biotherapeutics Charts.

SAB Biotherapeutics (NASDAQ:SABS)
Historical Stock Chart
Von Sep 2023 bis Sep 2024

Click Here for more SAB Biotherapeutics Charts.

News SAB Biotherapeutics Inc

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 13 August 2024 (1 Monat vor) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Montag 12 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 8 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Mittwoch 31 Juli 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 31 Juli 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 17 Juli 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 17 Juli 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 17 Juli 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 17 Juli 2024 (2 Monate vor) • Edgar (US Regulatory)

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
Montag 20 Mai 2024 (4 Monate vor) • GlobeNewswire Inc.

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
Montag 6 Mai 2024 (5 Monate vor) • GlobeNewswire Inc.

SAB Biotherapeutics Provides SAB-142 Trial Update
Dienstag 16 April 2024 (5 Monate vor) • GlobeNewswire Inc.

Weitere SAB Biotherapeutics Inc News-Artikel

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen